eLife Publishes AIMS Researcher’s Paper on HIV Treatment

“The HIV global pandemic is still very much pervasive across the globe,” said Eva Liliane Ujeneza. “Even though antiretroviral treatment (ART) counter’s the virus’ highly destructive effects on the immune system’s CD4 T cells, the response to treatment varies across patients, for reasons that are not fully understood. Our study uses a combined mathematical and empirical approach, to demonstrate how age, gender, and other parameters affect the recovery of CD4 T cells following treatment initiation, and how these effects vary over time,” she said.

“Several previous studies have quantified the effects of ART on the CD4 T cells,” said Prof Wilfred Ndifon, co-author and Chief Scientific Officer for AIMS. “These studies generally used so-called “semi-mechanistic” mathematical models, the analysis of which incorporated reference CD4 T cell counts from healthy individuals in an ad hoc way.” Eva’s study is the first to use a mathematical model that provides mechanistic insight into the changes that CD4 T cells undergo during ART while enabling systematic comparison with changes occurring in healthy individuals. We are excited about the imminent impact of the findings. One possible application is for projecting normal ranges of CD4 T cell recovery rates in paediatric HIV patients on ART, such that instances of abnormal recovery can be easily detected,” he said.

The raging COVID-19 pandemic has shifted focus from HIV/AIDS. According to UN AIDS, since the start of the HIV/AIDS pandemic, around 75 million people have become infected with HIV, and over 30 million people have died from AIDS-related diseases. HIV/AIDS is less devastating today, thanks to the development of ART, which many patients would have to receive throughout their lifetime to have a chance at leading a healthy life. This study analyses the long-term effects of protracted ART, highlighting the variations with age and gender. This research’s findings are relevant to public health actors (doctors, pharmaceutical companies, and Ministries of Public Health) in managing HIV/AIDS treatment. Read the article here.